HIF-1α expression regulates the bactericidal capacity of phagocytes

Journal of Clinical Investigation

Volumn 115, Issue 7, 2005, Pages 1806-1815

  Peyssonnaux, Carole ^a   Datta, Vivekanand ^b   Cramer, Thorsten ^a,e   Doedens, Andrew ^a   Theodorakis, Emmanuel A ^c   Gallo, Richard L ^b,d   Hurtado Ziola, Nancy ^d   Nizet, Victor ^b   Johnson, Randall S ^a,c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITRIC OXIDE; PEPTIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PROTEINASE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIMICROBIAL CATIONIC PEPTIDE; PEPTIDE HYDROLASE; TRANSCRIPTION FACTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BONE MARROW CELL; CELL ACTIVITY; CELL LINEAGE; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; GENE TARGETING; HYPOXIA; IMMUNE RESPONSE; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PHAGOCYTE; PRIORITY JOURNAL; PROTEIN INDUCTION; PROTEIN SYNTHESIS; SOFT TISSUE INFECTION; STREPTOCOCCUS GROUP A; ANIMAL; ANOXIA; BACTERIUM; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; IN VITRO STUDY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; STREPTOCOCCUS INFECTION; STREPTOCOCCUS PYOGENES;

ANIMALS; ANOXIA; ANTIMICROBIAL CATIONIC PEPTIDES; BACTERIA; BACTERIAL INFECTIONS; GENE EXPRESSION REGULATION; GENE TARGETING; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; IMMUNITY, NATURAL; MICE; MICE, KNOCKOUT; PEPTIDE HYDROLASES; PHAGOCYTES; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; TRANSCRIPTION FACTORS;

EID: 22144492953     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI23865     Document Type: Article

References (56)

1. Vogelberg, K.H., and Konig, M. 1993. Hypoxia of diabetic feet with abnormal arterial blood flow. Clin. Investig. 71:466-470.
2. Arnold, F., West, D., and Kumar, S. 1987. Wound healing: the effect of macrophage and tumour derived angiogenesis factors on skin graft vascularization. Br. J. Exp. Pathol. 68:569-574.
3. Negus, R.P., Stamp, G.W., Hadley, J., and Balkwill, F.R. 1997. Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150:1723-1734.
4. Semenza, G.L. 2001. HTF-1 and mechanisms of hypoxia sensing. Curr. Opin. Cell Biol. 13:167-171.
5. Flamme, I., et al. 1997. HRF, a putative basic helix-loop-helix-PAS- domain transcription factor is closely related to hypoxia-inducible factor-1α and developmentally expressed in blood vessels. Mech. Dev. 63:51-60.
6. Ema, M., et al. 1997. A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1α regulates the VEGF expression and is potentially involved in lung and vascular development. Proc. Natl. Acad. Sci. U. S. A. 94:4273-4278.
7. Tian, H., McKnight, S.L., and Russell, D.W. 1997. Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. Genes Dev. 11:72-82.
8. Gu, Y.Z., Moran, S.M., Hogenesch, J.B., Wartman, L., and BradfieLd, C.A. 1998. Molecular characterization and chromosomal localization of a third α-class hypoxia inducible factor subunit, HIF3α. Gene Expr. 7:205-213.
9. Burke, B., et al. 2002. Expression of HIF-1α by human macrophages: implications for the use of macrophages in hypoxia-regulated cancer gene therapy. J. Pathol. 196:204-212.
10. Hollander, A.P., Corke, K.P., Freemont, A.J., and Lewis, C.E. 2001. Expression of hypoxia-inducible factor 1α by macrophages in the rheumatoid synovium: implications for targeting of therapeutic genes to the inflamed joint. Arthritis Rheum. 44:1540-1544.
11. Cramer, T., et al. 2003. HIF-1α is essential for myeloid cell-mediated inflammation. Cell. 112:645-657.
12. Schwartz, R.H., Gerber, M.A., and McCoy, P. 1985. Effect of atmosphere of incubation on the isolation of group A streptococci from throat cultures. J. Lab. Clin. Med. 106:88-92.
13. Warnecke, C., et al. 2003. Activation of the hypoxia-inducible factor-pathway and stimulation of angiogenesis by application of prolyl hydroxylase inhibitors. FASEB J. 17:1186-1188.
14. Kong, T., Eltzschig, H.K., Karhausen, J., Colgan, S.P., and Shelley, C.S. 2004. Leukocyte adhesion during hypoxia is mediated by HIF-1-dependent induction of β2 incegrin gene expression. Proc. Natl. Acad. Sci. U. S. A. 101:10440-10445.
15. Reeves, E.P., et al. 2002. Killing activity of neutrophils is mediated through activation of proteases by K+ flux. Nature. 416:291-297.
16. Guyonnet, V., Johnson, J.K., Bangalore, N., Travis, J., and Long, P.L. 1991. In vitro activity of the human neutrophil cathepsin G on Eimeria tenella sporozoites. J. Parasitol. 77:775-779.
17. Miyasaki, K.T., and Bodeau, A.L. 1991. In vitro killing of oral Capnocytophaga by granule fractions of human neutrophils is associated with cathepsin G activity. J. Clin. Invest. 87:1585-1593.
18. Shafer, W.M., and Onunka, V.C. 1989. Mechanism of staphylococcal resistance to non-oxidative antimicrobial action of neutrophils: importance of pH and ionic strength in determining the bactericidal action of cathepsin G. J. Gen. Microbiol. 135:825-830.
19. Barrett, A.J. 1981. Cathepsin G. Methods Enzymol. 80:561-565.
20. Cole, A.M., et al. 2001. Inhibition of neutrophil elastase prevents cathelicidin activation and impairs clearance of bacteria from wounds. Blood. 97:297-304.
21. Sorensen, O.E., et al. 2001. Human cathelicidin, hCAP-18, is processed to the antimicrobial peptide LL-37 by extracellular cleavage with proteinase 3. Blood. 97:3951-3959.
22. Nizet, V., and Gallo, R.L. 2003. Cathelicidins and innate defense against invasive bacterial infection. Scand. J. Infect. Dis. 35:670-676.
23. Panyutich, A., Shi, J., Boutz, P.L., Zhao, C. and Ganz, T. 1997. Porcine polymorphonuclear leukocytes generate extracellular microbicidal activity by elastase-mediated activation of secreted proprotegrins. Infect. Immun. 65:978-985.
24. Nizet, V., et al. 2001. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Nature. 414:454-457.
25. Lirk, P., Hoffmann, G., and Rieder, J. 2002. Inducible nitric oxide synthase-time for reappraisal. Curr. Drug Targets Inflamm. Allergy. 1:89-108.
26. Gyurko, R., et al. 2003. Mice lacking inducible nitric oxide synthase demonstrate impaired killing of Porphyromonas gingivalis. Infect. Immun. 71:4917-4924.
27. Alani, M.S., et al. 2002. Role of nitric oxide in host defense in murine salmonellosis as a function of its antibacterial and antiapoptotic activities. Infect. Immun. 70:3130-3142.
28. Melillo, G., et al. 1997. Functional requirement of the hypoxia-responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J. Biol. Chem. 272:12236-12243.
29. Jung, F., Palmer, L.A., Zhou, N., and Johns, R.A. 2000. Hypoxic regulation of inducible nitric oxide synthase via hypoxia inducible factor-1 in cardiac myocytes. Circ. Res. 86:319-325.
30. Hu, R., Dai, A., and Tan, S. 2002. Hypoxia-inducible factor 1α upregulates the expression of inducible nitric oxide synthase gene in pulmonary arteries of hypoxic rat. Chin. Med. J. 115:1833-1837.
31. Thornton, R.D., et al. 2000. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem. J. 350:307-312.
32. Hellwig-Burgel, T., Rutkowski, K., Metzen, E., Fandrey, J., and Jelkmann, W. 1999. Interleukin-1β and tumor necrosis factor-α stimulate DNA binding of hypoxia-inducible factor-1. Blood. 94:1561-1567.
33. Sandau, K.B., Fandrey, J., and Brune, B. 2001. Accumulation of HIF-1α under the influence of nitric oxide. Blood. 97:1009-1015.
34. Zhou, J., Fandrey, J., Schumann, J., Tiegs, G., and Brune, B. 2003. NO and TNF-alpha released from activated macrophages stabilize HIF-1alpha in resting tubular LLC-PK1 cells. Am. J. Physiol. Cell Physiol. 284:C439-C446.
35. Zhou, J., Schmid, T., and Brune, B. 2003. Tumor necrosis factor-alpha causes accumulation of a ubiquitinated form of hypoxia inducible factor-1α through a nuclear factor-kappaB-dependent pathway. Mol. Biol. Cell. 14:2216-2225.
36. Kasuno, K., et al. 2004. Nitric oxide induces hypoxia-inducible factor 1 activation that is dependent on MAPK and phosphatidylinositol 3-kinase signaling. J. Biol. Chem. 279:2550-2558.
37. Chan, A.T., Cleeve, V., and Daymond, T.J. 2002. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. Postgrad. Med. J. 78:47-48.
38. Nemoto, Y., et al. 1999. Differential effects of interleukin-4 and interleukin-10 on nitric oxide production by murine macrophages. Inflamm. Res. 48:643-650.
39. Drapier, J.C., Wietzerbin, J., and Hibbs, J.B., Jr. 1988. Interferon-gamma and tumor necrosis factor induce the L-arginine-dependent cytotoxic effector mechanism in murine macrophages. Eur. J. Immunol. 18:1587-1592.
40. Corradin, S.B., et al. 1993. Induction of macrophage nitric oxide production by interferon-gamma and tumor necrosis factor-alpha is enhanced by interleukin-10. Eur. J. Immunol 23:2045-2048.
41. Eigler, A., Moeller, J., and Endres, S. 1995. Exogenous and endogenous nitric oxide attenuates tumor necrosis factor synthesis in the murine macrophage cell line RAW 264.7. J. Immunol. 154:4048-4054.
42. Marcinkiewicz, J., Grabowska, A., and Chain, B. 1995. Nitric oxide up-regulates the release of inflammatory mediators by mouse macrophages. Eur. J. Immunol. 25:947-951.
43. Kuo, H.P., et al. 2000. Nitric oxide modulates interleukin-1beta and tumor necrosis factor-alpha synthesis by alveolar macrophages in pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 161:192-199.
44. Iuvone, T., D'Acquisto, F., Carnuccio, R., and Di Rosa, M. 1996. Nitric oxide inhibits LPS-induced tumor necrosis factor synthesis in vitro and in vivo. Life Sci. 59:PL207-PL211.
45. Wu, C.H., et al. 2003. Nitric oxide modulates pro-and anti-inflammatory cytokines in lipopolysaccharide-activated macrophages. J. Trauma. 55:540-545.
46. Griffiths, L., et al. 2000. The macrophage - a novel system to deliver gene therapy to pathological hypoxia. Gene Ther. 7:255-262.
47. Talks, K.L., et al. 2000. The expression and distribution of the hypoxia-inducible factors HIF-1α and HIF-2α in normal human tissues, cancers, and tumor-associated macrophages. Am. J. Pathol. 157:411-421.
48. Nathan, C. 2003. Immunology: oxygen and the inflammatory cell. Nature. 422:675-676,
49. Stricter, R.M. 2003. Mastering innate immunity. Nat. Med. 9:512-513.
50. Clausen, B.E., Burkhardt, C., Reith, W., Renkawitz, R., and Forster, I. 1999. Conditional gene targeting in macrophages and granulocytes using LysMcre mice. Transgenic Res. 8:265-277.
51. Walmsley, S.R., et al. 2005. Hypoxia-induced neutrophil survival is mediated by HIF-1α-dependent NF-κB activity. J. Exp. Med. 201:105-115.
52. Kansal, R.G., McGeer, A., Low, D.E., Norrby-Teglund, A., and Kotb, M. 2000. Inverse relation between disease severity and expression of the streptococcal cysteine protease, SpeB, among clonal M1T1 isolates recovered from invasive group A streptococcal infection cases. Infect. Immun. 68:6362-6369.
53. Liu, G.Y., et al. 2004. Sword and shield: linked group B streptococcal β-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc. Natl. Acad. Sci. U. S. A. 101:14491-14496.
54. Humar, D., et al. 2002. Strepcolysin S and necrotising infections produced by group G streptococcus. Lancet. 359:124-129.
55. Grunstein, J., Roberts, W.G., Mathieu-Costello, O., Hanahan, D., and Johnson, R.S. 1999. Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Res. 59:1592-1598.
56. Blouw, B., et al. 2003. The hypoxic response of tumors is dependent on their micro environment. Cancer Cell. 4:133-146.